Background

The nebuliser technology enables inhalation delivery of a wide range of drugs, including marketed formulations and novel high value therapeutics such as biologics, nanomedicines and vaccines. Current nebuliser technologies have limited acceptable formulation; delivery of formulations with low surface tension, suspensions and biologics has proven to be challenging with current devices. This has resulted in limited availability of drugs for patients.

The majority of global pandemics, such as COVID-19, are respiratory infections and the availability of more efficient inhalation drug delivery devices could reduce the drug development time and accelerate the availability of new drugs (e.g. small molecule and biological vaccination). Furthermore, some of the proposed treatment for SARS-CoV-2 infection are re-purposed drugs that are not available in